Patent ID: 8664184

Claim:
A method of treating cancer in a human comprising: administering to the human a therapeutically effective amount of Clostridium perfringens enterotoxin (CPE) or a pharmaceutically effective salt thereof; wherein the cancer is recurrent ovarian serous papillary carcinoma, recurrent ovarian clear cell carcinoma, or recurrent uterine serous papillary carcinoma, wherein said recurrent cancer includes chemotherapy-resistant malignant cells which express claudin 3 and/or claudin-4 receptors at a significantly higher level than naïve chemotherapy-sensitive malignant cells; wherein the CPE is native CPE (SEQ ID NO:1) or a variant thereof comprising a sequence at least 90% identical to residues 45-319 of SEQ ID NO:1; wherein the CPE or a pharmaceutically acceptable salt thereof is administered intravenously or intraperitoneally and wherein the CPE preferably binds to chemotherapy-resistant cancerous cells over chemotherapy-sensitive cancer cells.